This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Mark Shearman, PhD
Executive Vice President and Chief Scientific Officer at Editas Medicine


Mark is Executive Vice President and Chief Scientific Officer of Editas Medicine. He joined Editas Medicine in June 2021 and is responsible for leading the drug discovery activities related to Editas Medicine’s pipeline of experimental medicines across all indications.
Mark brings to Editas more than 30 years of experience in drug discovery and development across multiple therapeutic modalities. Mark joins Editas Medicine from Applied Genetic Technologies Corporation (AGTC), where he served as Chief Scientific Officer and was responsible for leading the company's product candidate selection process, pre-clinical and translational research, and long-term research and development planning. Prior to AGTC, Mark served as Senior Vice President of Research & Early Development at EMD Serono, Inc., the U.S. and Canadian subsidiary of Merck KGaA. Previously, Mark was Executive Director of Merck & Co. Research Laboratories, Boston, and Senior Director at the Merck Sharp & Dohme Research Laboratories Neuroscience Research Centre in the United Kingdom.
Prior to his career in Industry, Mark pursued academic science, having been awarded post-doctoral fellowships with Yasutomi Nishizuka (Kobe Medical School, Japan) and Axel Ullrich (Max Planck Institute, Munich, Germany). Mark has co-authored more than 130 research publications (Nature, Cell, PNAS, EMBO J, JBC, Human Gene Therapy); has been an invited speaker at more than 65 national and international meetings; and served on numerous editorial, grant review, scientific advisory boards and expert advisory panels.
Mark earned a B.Sc. from the University of Bristol, U.K., and a Ph.D. from the University of Nottingham, U.K.

Agenda Sessions

  • Ongoing Progress in the Phase 1/2 BRILLIANCE Clinical Trial for Treatment of CEP-290 Retinal Degeneration


Speakers at this event